SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Depotech(depo) -- Ignore unavailable to you. Want to Upgrade?

To: BD who wrote (680)1/7/1998 1:23:00 PM
From: Czechsinthemail  Respond to of 887
 
DEPO is continuing to inch higher. Very impressive in a market that has been generally weak. The strength suggests a shift from selling to bargain hunting. I think it bodes well for further recovery.
Baird



To: BD who wrote (680)1/7/1998 1:29:00 PM
From: tnsaf  Read Replies (1) | Respond to of 887
 
A recent issue of Medical Technology Stock Letter had a comment about DepoCyte in its review of Chiron, which is DEPO's partner on the compound. It says DepoCyte is likely to be approved sometime this year. Given the crushed expectations from the ODAC meeting, I'd guess that DEPO won't be saying much to revive those expectations.

Jason


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News